Intelligenome

8955 Interchange Drive
Houston,  TX  77054

United States
https://intelligenome-us.com/

• Booth: 1986

 Press Releases

• IGDx Inc (dba IntelliGenome) (Feb 13, 2024)
      IGDX, Inc. develops diagnostic technology for the world’s serious health challenges and our vision is a diagnostic platform that transforms the lives of people impacted by infectious disease. We have developed and validated ultra-sensitive CRISPR-based detection of low abundance nucleic acid in small volume blood samples.
      The first commercialization of our technology will be a first one Mycobacterium tuberculosis point-of-care detection test in blood sample, capable of delivering accurate and reliable results in hours. Our CRISPR-based platform will be ready to combat future infectious disease outbreaks ranging from non-Tuberculosis Mycobacterium (NTM) infections and HIV to global challenges posed by SARS and other emerging diseases.
      Our team is in pursuit of a future where point-of-care disease diagnosis is not only accurate, affordable and rapid, but also an instrument of positive transformation, particularly in low-and-medium income countries.